CARL ZEISS MEDITEC AG Carl Zeiss Meditec AG Stock Börse Stuttgart
Equities
AFX
DE0005313704
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 91.65 EUR | -2.81% |
|
-1.10% | -4.05% |
| May. 23 | Goldman downgrades Carl Zeiss Meditec to 'Sell' - Target 90 euros | DP |
| May. 23 | CARL ZEISS MEDITEC AG : Downgraded from Neutral to Sell by Goldman Sachs | ZD |
| Sales 2024 * | 2.23B 2.41B | Sales 2025 * | 2.51B 2.71B | Capitalization | 8.26B 8.93B |
|---|---|---|---|---|---|
| Net income 2024 * | 255M 276M | Net income 2025 * | 316M 342M | EV / Sales 2024 * | 3.88 x |
| Net Debt 2024 * | 396M 428M | Net Debt 2025 * | 345M 373M | EV / Sales 2025 * | 3.43 x |
| P/E ratio 2024 * |
32.4
x | P/E ratio 2025 * |
26.1
x | Employees | - |
| Yield 2024 * |
1.14% | Yield 2025 * |
1.3% | Free-Float | 40.86% |
More Fundamentals
* Assessed data
More news
Latest transcript on Carl Zeiss Meditec AG
More recommendations
More press releases
More news
| 1 week | -5.12% | ||
| Current month | -7.28% | ||
| 1 month | -11.11% | ||
| 3 months | -18.97% | ||
| 6 months | +5.25% | ||
| Current year | -6.75% |
1 week
90.75
96.60
1 month
90.75103.60
3 years
72.72201.80
5 years
67.70201.80
10 years
19.84201.80
| Managers | Title | Age | Since |
|---|---|---|---|
Markus Weber
CEO | Chief Executive Officer | 51 | 21-12-30 |
| Director of Finance/CFO | 59 | 18-09-30 | |
Christian Müller
BRD | Director/Board Member | 57 | 09-12-14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michael Kaschke
BRD | Director/Board Member | 66 | 01-12-31 |
Peter Kameritsch
BRD | Director/Board Member | 55 | 21-05-26 |
Heike Madan
BRD | Director/Board Member | 52 | 23-03-21 |
| Date | Price | Change |
|---|---|---|
| 24-05-23 | 91.65 | -2.81% |
| 24-05-22 | 94.3 | +1.29% |
| 24-05-21 | 93.1 | -2.77% |
| 24-05-20 | 95.75 | +0.74% |
| 24-05-17 | 95.05 | -1.60% |
Delayed Quote Börse Stuttgart, May 23, 2024 at 03:55 pm EDT
More quotes
Carl Zeiss Meditec AG is a Germany-based medical technology and device company. It offers offers complete solutions to diagnose and treat ophtalmic diseases, visualization solutions for microsurgery and other technologies, such as intraoperative radiotherapy. The Company operates in two segments: Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment comprises activities in the area of ophthalmology, such as intraocular lenses, surgical visualization solutions and medical laser and diagnostic systems. The Microsurgery segment includes activities of neuro, ear, nose and throat surgery, as well as the activities in the field of intraoperative radiation. The Company has various production sites in Europe, the United States and Asia.
Calendar
2024-08-08
- Q3 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
15
Last Close Price
92.35
EUR
Average target price
104.2
EUR
Spread / Average Target
+12.83%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +10.22% | 226B | |
| +12.99% | 198B | |
| +18.09% | 142B | |
| +28.66% | 111B | |
| +2.09% | 65.26B | |
| +14.70% | 54.36B | |
| +6.68% | 50.94B | |
| +8.29% | 44.8B | |
| +2.60% | 36.8B |
- Stock Market
- Equities
- AFX Stock
- AFX Stock
